Using cell and gene therapy to treat neuroendocrine tumors
Allogeneic cell and gene therapy for neuroendocrine tumors
This study is testing new treatments using donor cells to help fight rare neuroendocrine tumors, aiming to see how safe and effective these therapies are for patients who don’t have many options right now.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Expression Therapeutics NIH-funded |
| Lab location | 1 site (Tucker, United States) |
| Project ID | NIH-11066857 on NIH RePORTER |
What this research studies
This research focuses on developing innovative cell and gene therapies specifically for neuroendocrine tumors (NETs), which are rare cancers originating from neuroendocrine cells. The approach involves utilizing allogeneic cells, which are derived from a donor, to target and potentially eliminate tumor cells. Patients may receive these therapies through injections or infusions, and the research aims to assess the safety and effectiveness of these treatments in managing NETs. By leveraging advanced techniques in cell therapy, the study seeks to improve outcomes for patients who currently have limited treatment options.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with neuroendocrine tumors who have not responded adequately to existing therapies.
Not a fit: Patients with localized, surgically removable neuroendocrine tumors may not benefit from this research as they might be better suited for surgical intervention.
Why it matters
Potential benefit: If successful, this research could provide a new, effective treatment option for patients with neuroendocrine tumors, potentially improving survival rates and quality of life.
How similar studies have performed: While the use of cell and gene therapies is a growing field, this specific approach for neuroendocrine tumors is relatively novel and has not been extensively tested in prior studies.
Where this research is happening
Tucker, United States
- Expression Therapeutics — Tucker, United States (Active)
Researchers
- Principal investigator: Petrich, Brian G — Expression Therapeutics
- Study coordinator: Petrich, Brian G
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.